Catálogo de publicaciones - revistas

<jats:p>Therapeutic proteins may first be developed as intravenous (i.v.) therapies with new subcutaneous (s.c.) dosage forms being subsequently developed to provide an alternative route of administration. As of August 2022, there have been 9 therapeutic proteins which were developed as a new s.c. dosage form after the approval of the corresponding i.v. product. This article provides a systematic review of prior experiences in the i.v. to s.c. switch development programs. We describe what types of clinical studies were conducted to support the i.v. to s.c. switch for these nine therapeutic proteins. Publicly available scientific advice from health authorities is summarized, particularly regarding recommendations on overall development strategy, dose selection, immunogenicity assessment, and indication extrapolation. The clinical data from these i.v. to s.c. development programs demonstrate that: (1) when switching from i.v. dosing to s.c. dosing, trough drug concentration (<jats:italic>C</jats:italic><jats:sub>trough</jats:sub>) from s.c. dosing should not be inferior to i.v. dosing with average drug concentration (<jats:italic>C</jats:italic><jats:sub>avg</jats:sub>; equivalent to AUC, area under the curve after correcting for dosing intervals between i.v. and s.c. administration) being matched or non‐inferior to i.v. dosing; and (2) with appropriate s.c. dose regimens, treatment with s.c. therapeutic proteins can generally achieve similar efficacy and safety as the corresponding i.v. products, suggesting that the much higher maximum concentration (<jats:italic>C</jats:italic><jats:sub>max</jats:sub>) after i.v. infusion as compared with that from s.c. injection is often not relevant to the treatment effect.</jats:p>